Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc. on September 2, 2025. The Company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbols BIAF (Common Stock) and BIAFW (Warrants). The report details a material definitive agreement regarding warrant amendments effective as of August 12, 2025.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a warrant amendment agreement.
Material Changes
The Company entered into an agreement with holders of the May 2025 Warrants and August 2025 Warrants to amend the Floor Price. Key changes include:
- Floor Price Adjustment: The Floor Price was increased from $0.10 to $0.15.
- May 2025 Warrants: As a result of the price increase, the total number of shares issuable upon exercise was reduced from 53,377,497 to 35,584,997.
- August 2025 Warrants: These warrants remain subject to shareholder approval.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies were disclosed beyond the standard qualification that the descriptions of the warrant amendments are not complete and are qualified by the full text of the attached exhibits.
Investor Verification Checklist
- Verify the full text of the May 2025 Warrant Amendment (Exhibit 4.1) and August 2025 Warrant Amendment (Exhibit 4.2) for complete terms.
- Confirm the status of shareholder approval required for the August 2025 Warrants.
- Review the impact of the reduced share count (35,584,997 shares) on potential future dilution.
- Check subsequent filings for any updates regarding the shareholder vote on the August 2025 Warrants.